Old Web
English
Sign In
Acemap
>
authorDetail
>
Raffaele Baffa
Raffaele Baffa
Pfizer
Medicine
Antibody-drug conjugate
Internal medicine
Pharmacokinetics
Cancer research
4
Papers
39
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody–drug conjugate, in patients with breast cancer and other advanced solid tumors
2019
Investigational New Drugs
Lee S. Rosen
Robert Wesolowski
Raffaele Baffa
Kai-Hsin Liao
Steven Y. Hua
Brenda Gibson
Steven Pirie-Shepherd
Anthony W. Tolcher
Show All
Source
Cite
Save
Citations (17)
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors: PF-06647263 in patients with solid tumors
2019
International Journal of Cancer
Ignacio Garrido–Laguna
Ian E. Krop
Howard A. Burris
Erika Paige Hamilton
Fadi Braiteh
Amy Weise
Maysa Abu-Khalaf
Theresa L. Werner
Steven Pirie-Shepherd
Christopher J. Zopf
Mani Lakshminarayanan
Jaymes S. Holland
Raffaele Baffa
David S. Hong
Show All
Source
Cite
Save
Citations (12)
A phase I study of PF-06647263, a novel EFNA4-ADC, in patients with metastatic triple negative breast cancer.
2017
Journal of Clinical Oncology
Ignacio Garrido–Laguna
Ian E. Krop
Howard A. Burris
Erika Paige Hamilton
Fadi S. Braiteh
A. Weise
Maysa Abu-Khalaf
Christopher J. Zopf
Mani Lakshminarayanan
Jaymes S. Holland
Raffaele Baffa
David S. Hong
Raffit Hassan
Show All
Source
Cite
Save
Citations (6)
30LBA A Phase 1 dose escalation, safety, and pharmacokinetic study of PF-06650808, an anti-Notch3 antibody drug conjugate, in adult patients with advanced solid tumors
2015
European Journal of Cancer
Lee S. Rosen
Robert Wesolowski
Brenda Gibson
Raffaele Baffa
K. H. Liao
J Masters
Steven Y. Hua
S. Deng
R. Shazer
Anthony W. Tolcher
Show All
Source
Cite
Save
Citations (4)
1